LEVERAGE LONG - ELI LILLY & CO | Market Closed - Borsa Italiana 21:04:59 17/05/2024 BST | ||
| 43.57 EUR | -2.90% |
|
| Current month | -14.27% | ||
| 1 month | -2.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 43.42 | -3.23% |
| 16/05/24 | 44.87 | -8.15% |
| 15/05/24 | 48.85 | +14.89% |
| 14/05/24 | 42.52 | +3.40% |
| 13/05/24 | 41.12 | -2.61% |
Real-time Borsa Italiana
Last update May 17, 2024 at 09:04 pm
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| SLLY5L | |
| ISIN | DE000SU2FTN1 |
| Date issued | 24/11/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 21.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 67.9 € |
|---|---|
| Lowest since issue | 14.05 € |
| Spread | 0.25 € |
| Spread % | 0.57% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- SLLY5L Certificat
